DrukerB.J., LydonN.B.: Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.J Clin Invest, 105: 3–7, 2000.
2.
DrukerB.J., TamuraS., BuchdungerE.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.Nat Med, 2: 561–566, 1996.
3.
GambacortiC., PasseriniP., Le CoutreP., MologniL., BertazzoliC., MarchesiA., BiondiG.M., CorneoE., PoglianiN., LydonB.: Inhibition of the ABL kinase activity selectively blocks the growth of BCR/ABL+ leukemic cells and induces apoptosis.Blood Cells, Molecules & Diseases, 23: 380–394, 1997.
4.
Le CoutreP., MologniL., ClerisL.F., FormelliC., GambacortiC., PasseriniP.: In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.J Natl Cancer Inst, 91: 163–168, 1999.
5.
DrukerB.J., TalpazM., RestaD.J.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.N Engl J Med, 344: 1038–1042, 2001.
6.
DrukerB.J., SawyersC.L., KantarjianH.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.N Engl J Med, 344: 1038–1042, 2001.
7.
Le CoutreP., TassiE., Varella-GarciaM., BarniR., MologniL., CabritaG., MarchesiE., SupinoR., GambacortiC., PasseriniP.: Induction of resistance to the Abelson inhibitor STI571 in human leukemia cells through gene amplification.Blood, 95: 1758–1766, 2000.
8.
GambacortiC., PasseriniP., BarniR., Le CoutreP., ZucchettiM., CabritaG., ClerisL., RossiF., GianazzaE., BrueggenJ., CozensR., PioltelliP., PoglianiE., CorneoG., FormelliF., D'IncalciM.: Role of 1 acid glycoprotein in the in vivo resistance of human BCR-ABL + leukemia cells to the ABL inhibitor STI571.J Natl Cancer Inst, 92: 1641–1650, 2000.
9.
JoensuuH., RobertsP.J., Sarlomo-RikalaM.: Effects of tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.N Engl J Med, 344: 1052–1056, 2001.
